


MKPAG Bulletin

(Milton Keynes Prescribing Advisory Group)



 http://www.formularymk.nhs.uk	MKUH NHS FT	http://www.mkhospital.nhs.uk/
	MK CCG	http://www.miltonkeynesccg.nhs.uk/
	CNWL - MK	http://www.cnwl.nhs.uk/

The purpose of the MKPAG bulletin is to deliver succinct, evidence-based advice and information on primary and secondary care prescribing issues. Aimed at busy prescribers wanting to know key messages from MKPAG.

Summary of May 2015 Decisions

Medicine	Classification	Indication	Other Information
Empagliflozin (Jardiance®) ▼ 10mg and 25mg film-coated tablets	Blue	In combination therapy for treatment of Type 2 Diabetes	The review of this class of new antidiabetic medicines is being carried out by a sub-committee to determine how these medicines will be used in relation to other options; recommendations will be made based on local consensus
Rifaximin (Targaxan®) ▼ 550mg film-coated tablets	Amber	Use in preventing episodes of overt hepatic encephalopathy	Secondary Care initiation and GP continuation
Pomalidomide (Imnovid®) Capsules	Not recommended by NICE		

News from MKPAG

Recent updates to the Milton Keynes Formulary website

- The "Application to add a medicine to the formulary" form has been updated. The newly updated form which is available on the [formulary website](#) requires the applications to be signed off by the Finance Business Partner for the Clinical Service Unit (in Hospital) before submitting applications to MKPAG
- Prescribing Guidelines for open angle glaucoma and ocular hypertension are now available

Coming soon to the Milton Keynes Formulary website

- Emollient and Barrier Preparation – Prescribing guideline
- Chronic Pain Management – Prescribing guidelines
- Shared Care Guideline for Eprex Injection
- Shared Care Guideline for Methotrexate in Rheumatoid Arthritis
- Shared Care Guideline for Sulfasalazine in Rheumatoid Arthritis
- Shared Care Guideline for Hydroxychloroquine in Rheumatoid Arthritis
- Shared Care Guideline for Leflunomide in Rheumatoid Arthritis
- Shared Care Guideline for Azathioprine in Rheumatoid Arthritis
- Shared Care Guideline for Ciclosporin in Rheumatoid Arthritis
- Shared Care Guideline for Penicillamine in Rheumatoid Arthritis
- Alcohol dependence – local pathway

Upcoming new medicine applications / submissions for consideration at July 2015 MKPAG

- Melatonin for insomnia in patients with Parkinson's disease (Unlicensed use)
- Mesalazine - Octasa® brand for treatment of mild to moderate ulcerative colitis and maintenance of remission and Crohn's ileo- colitis
- Aripiprazole and Paliperidone – (mental health)



Horizon Scanning

Horizon scanning aims to identify in advance treatments that may have significant implications for clinical practice, service design or finance that are likely to become available to the NHS. Horizon scanning should also identify potential disinvestments by reviewing evidence on an on-going basis.

By horizon scanning for medicines and treatments, providers and commissioners may be able to make proactive commissioning decisions and minimise problems created by in-year requests. This could include making interim policy decisions and financial provision for in-year developments, if necessary.

Further details will be published with the next issue.....

Did you know?

Valproate is now a black triangle ▼ drug. The MHRA has issued a letter warning about risks of valproate exposure in pregnancy and advising that its use should be avoided in women and girls unless other treatments are not effective or tolerated. Valproate is now a black triangle medicine, and all adverse effects should be reported via the [Yellow Card scheme](#).

Patent Expiries		
JUNE Nepafenac, Tenecteplase	JULY Rasburicase	AUGUST Bivalirudin, Strontium, ranelate
SEPTEMBER Tiotropium, Sirolimus, Nateglinide, Etoricoxib	OCTOBER Alitretinoin, Etanercept	NOVEMBER Pimecrolimus, Palonosetron
DECEMBER Pemetrexed, disodium Frovatriptan, Lopinavir, Ritonavir, Eletriptan, Travoprost		

Upcoming NICE guidance expected in June / July 2015		
Title	Type	Clinical speciality
Treatment and secondary prevention DVT, PE - apixaban	NICE TA*	Cardiovascular
Constipation – opioid induced - naloxegol	NICE TA	Gastrointestinal
Macular oedema (diabetic) - dexamethasone intravitreal implant	NICE TA	Endocrine
Hepatitis C (chronic) - ledipasvir-sofosbuvir	NICE TA	Infection
Macular oedema (diabetic) - aflibercept	NICE TA	Eye, Ear, Nose & Throat
Macular oedema (diabetic) - dexamethasone intravitreal implant	NICE TA	Eye, Ear, Nose & Throat
Prostate cancer (advanced, hormone dependent) - degarelix depot	NICE TA	Malignant Disease
Systemic lupus erythematosus (autoantibody-positive) - belimumab	NICE TA	Musculoskeletal & Joints
Ulcerative colitis (moderate to severely active) - vedolizumab	NICE TA	Gastrointestinal
Urticaria (chronic spontaneous, previously treated) - omalizumab	NICE TA	Skin
Crohn's disease (moderate to severe) - vedolizumab	NICE TA	Gastrointestinal
Psoriatic arthritis (active) - ustekinumab	NICE TA	Musculoskeletal & Joints

NICE TA* = NICE Technology Appraisal

The work of MKPAG is supported and managed by the team below. If you would like to make a submission or have any queries, they can be contacted via the formulary website www.formularymk.nhs.uk

Formulary Project Team - Lead & Supported by: Dupe Fagbenro dupe.fagbenro@mkhospital.nhs.uk

MKPAG for the Milton Keynes Health Community on behalf of:
Milton Keynes University Hospital NHS Foundation Trust
Milton Keynes Clinical Commissioning Group
Milton Keynes Community Health Services – CNWL-MK

© Milton Keynes University Hospital NHS Foundation Trust, Standing Way, Eaglestone, Milton Keynes, MK6 5LD